BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
See today's BioWorld
Home
» Much-awaited FDA nod comes early for Exelixis' cabo in renal cell carcinoma
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Much-awaited FDA nod comes early for Exelixis' cabo in renal cell carcinoma
April 26, 2016
By
Jennifer Boggs
No Comments
Exelixis Inc. will waste no time making Cabometyx (cabozantinib) available to advanced renal cell carcinoma (RCC) patients who have received prior anti-angiogenic therapy, following the FDA's widely anticipated approval Monday.
BioWorld